In Vivo Tau, Amyloid, and Gray Matter Profiles in the Aging Brain
暂无分享,去创建一个
Keith A. Johnson | R. Sperling | J. Sepulcre | A. Schultz | J. Chhatwal | M. Sabuncu | T. Gómez-Isla | Alex A Becker
[1] Reisa A. Sperling,et al. Harvard Aging Brain Study: Dataset and accessibility , 2017, NeuroImage.
[2] Daniel R. Schonhaut,et al. PET Imaging of Tau Deposition in the Aging Human Brain , 2016, Neuron.
[3] Jorge Sepulcre,et al. Tau positron emission tomographic imaging in aging and early Alzheimer disease , 2016, Annals of neurology.
[4] Keith A. Johnson,et al. Validating novel tau positron emission tomography tracer [F‐18]‐AV‐1451 (T807) on postmortem brain tissue , 2015, Annals of neurology.
[5] C. Jack. PART and SNAP , 2014, Acta Neuropathologica.
[6] Janna H. Neltner,et al. Primary age-related tauopathy (PART): a common pathology associated with human aging , 2014, Acta Neuropathologica.
[7] J. Ávila,et al. The role of extracellular Tau in the spreading of neurofibrillary pathology , 2014, Front. Cell. Neurosci..
[8] D. Bennett,et al. A 2-process model for neuropathology of Alzheimer's disease , 2014, Neurobiology of Aging.
[9] Min-Ying Su,et al. Early clinical PET imaging results with the novel PHF-tau radioligand [F18]-T808. , 2014, Journal of Alzheimer's disease : JAD.
[10] Vincent Doré,et al. In vivo evaluation of a novel tau imaging tracer for Alzheimer’s disease , 2014, European Journal of Nuclear Medicine and Molecular Imaging.
[11] Brian J. Bacskai,et al. Neurofibrillary tangle-bearing neurons are functionally integrated in cortical circuits in vivo , 2013, Proceedings of the National Academy of Sciences.
[12] Keith A. Johnson,et al. A concise radiosynthesis of the tau radiopharmaceutical, [(18) F]T807. , 2013, Journal of labelled compounds & radiopharmaceuticals.
[13] J. Trojanowski,et al. Imaging of Tau Pathology in a Tauopathy Mouse Model and in Alzheimer Patients Compared to Normal Controls , 2013, Neuron.
[14] H. Arai,et al. Novel 18F-Labeled Arylquinoline Derivatives for Noninvasive Imaging of Tau Pathology in Alzheimer Disease , 2013, The Journal of Nuclear Medicine.
[15] Alex Becker,et al. In vivo characterization of the early states of the amyloid-beta network. , 2013, Brain : a journal of neurology.
[16] B. Hyman,et al. Mechanisms of protein seeding in neurodegenerative diseases. , 2013, JAMA neurology.
[17] Clifford R. Jack,et al. Does amyloid deposition produce a specific atrophic signature in cognitively normal subjects?☆ , 2013, NeuroImage: Clinical.
[18] Min-Ying Su,et al. Early clinical PET imaging results with the novel PHF-tau radioligand [F-18]-T807. , 2013, Journal of Alzheimer's disease : JAD.
[19] B. Hyman,et al. Propagation of Tau Pathology in a Model of Early Alzheimer’s Disease , 2012, Neuron.
[20] Karen F Berman,et al. The neurobiology of Alzheimer disease defined by neuroimaging. , 2012, Current opinion in neurology.
[21] Nick C Fox,et al. Brain imaging in Alzheimer disease. , 2012, Cold Spring Harbor perspectives in medicine.
[22] M. Weiner,et al. A Network Diffusion Model of Disease Progression in Dementia , 2012, Neuron.
[23] Efstathios D. Gennatas,et al. Predicting Regional Neurodegeneration from the Healthy Brain Functional Connectome , 2012, Neuron.
[24] J. Schneider,et al. National Institute on Aging–Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease , 2012, Alzheimer's & Dementia.
[25] Andrei G. Vlassenko,et al. Amyloid‐beta plaque growth in cognitively normal adults: Longitudinal [11C]Pittsburgh compound B data , 2011, Annals of neurology.
[26] B. Hyman,et al. Neuropathological alterations in Alzheimer disease. , 2011, Cold Spring Harbor perspectives in medicine.
[27] M. Weiner,et al. The dynamics of cortical and hippocampal atrophy in Alzheimer disease. , 2011, Archives of neurology.
[28] Keith A. Johnson,et al. Amyloid-β Associated Cortical Thinning in Clinically Normal Elderly , 2011, Annals of neurology.
[29] Susan M Resnick,et al. In vivo fibrillar beta-amyloid detected using [11C]PiB positron emission tomography and neuropathologic assessment in older adults. , 2011, Archives of neurology.
[30] C. Rowe,et al. Longitudinal assessment of Aβ and cognition in aging and Alzheimer disease , 2011, Annals of neurology.
[31] Marine Fouquet,et al. Sequential relationships between grey matter and white matter atrophy and brain metabolic abnormalities in early Alzheimer's disease. , 2010, Brain : a journal of neurology.
[32] B. Miller,et al. Neurodegenerative Diseases Target Large-Scale Human Brain Networks , 2009, Neuron.
[33] Akram Bakkour,et al. The cortical signature of prodromal AD , 2009, Neurology.
[34] Keith A. Johnson,et al. Cortical Hubs Revealed by Intrinsic Functional Connectivity: Mapping, Assessment of Stability, and Relation to Alzheimer's Disease , 2009, The Journal of Neuroscience.
[35] J. Morris,et al. The Cortical Signature of Alzheimer's Disease: Regionally Specific Cortical Thinning Relates to Symptom Severity in Very Mild to Mild AD Dementia and is Detectable in Asymptomatic Amyloid-Positive Individuals , 2008, Cerebral cortex.
[36] Akram Bakkour,et al. The cortical signature of prodromal AD Regional thinning predicts mild AD dementia , 2009 .
[37] S. DeKosky,et al. Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer's disease , 2008, Brain : a journal of neurology.
[38] Yvette I. Sheline,et al. Potential antecedent marker of Alzheimer disease , 2006 .
[39] Vladimir Batagelj,et al. Exploratory Social Network Analysis with Pajek: Revised and Expanded Edition for Updated Software , 2018 .
[40] S. DeKosky,et al. Simplified quantification of Pittsburgh Compound B amyloid imaging PET studies: a comparative analysis. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[41] David C. Van Essen,et al. A Population-Average, Landmark- and Surface-based (PALS) atlas of human cerebral cortex , 2005, NeuroImage.
[42] Benjamin J. Shannon,et al. Molecular, Structural, and Functional Characterization of Alzheimer's Disease: Evidence for a Relationship between Default Activity, Amyloid, and Memory , 2005, The Journal of Neuroscience.
[43] R. Buckner. Memory and Executive Function in Aging and AD Multiple Factors that Cause Decline and Reserve Factors that Compensate , 2004, Neuron.
[44] M. Mattson. Pathways towards and away from Alzheimer's disease , 2004, Nature.
[45] D. Selkoe,et al. Oligomers on the brain: the emerging role of soluble protein aggregates in neurodegeneration. , 2004, Protein and peptide letters.
[46] M. Greicius,et al. Default-mode network activity distinguishes Alzheimer's disease from healthy aging: Evidence from functional MRI , 2004, Proc. Natl. Acad. Sci. USA.
[47] M. Albert,et al. Early Aβ accumulation and progressive synaptic loss, gliosis, and tangle formation in AD brain , 2004, Neurology.
[48] W. Klunk,et al. Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound‐B , 2004, Annals of neurology.
[49] H. Braak,et al. Neuropathological stageing of Alzheimer-related changes , 2004, Acta Neuropathologica.
[50] W. Klunk,et al. Synthesis and evaluation of 11C-labeled 6-substituted 2-arylbenzothiazoles as amyloid imaging agents. , 2003, Journal of medicinal chemistry.
[51] Jean-Claude Baron,et al. Early diagnosis of alzheimer’s disease: contribution of structural neuroimaging , 2003, NeuroImage.
[52] H. Braak,et al. Phases of Aβ-deposition in the human brain and its relevance for the development of AD , 2002, Neurology.
[53] Karl J. Friston,et al. Voxel-Based Morphometry—The Methods , 2000, NeuroImage.
[54] J. Morris,et al. Tangles and plaques in nondemented aging and “preclinical” Alzheimer's disease , 1999, Annals of neurology.
[55] N. Foster,et al. Metabolic reduction in the posterior cingulate cortex in very early Alzheimer's disease , 1997, Annals of neurology.
[56] Y. Benjamini,et al. Controlling the false discovery rate: a practical and powerful approach to multiple testing , 1995 .
[57] P. Scheltens,et al. Atrophy of medial temporal lobes on MRI in "probable" Alzheimer's disease and normal ageing: diagnostic value and neuropsychological correlates. , 1992, Journal of neurology, neurosurgery, and psychiatry.
[58] C. Jack,et al. MR‐based hippocampal volumetry in the diagnosis of Alzheimer's disease , 1992, Neurology.
[59] H. Braak,et al. Demonstration of Amyloid Deposits and Neurofibrillary Changes in Whole Brain Sections , 1991, Brain pathology.
[60] G. V. Van Hoesen,et al. The topographical and neuroanatomical distribution of neurofibrillary tangles and neuritic plaques in the cerebral cortex of patients with Alzheimer's disease. , 1991, Cerebral cortex.
[61] David J. Schlyer,et al. Graphical Analysis of Reversible Radioligand Binding from Time—Activity Measurements Applied to [N-11C-Methyl]-(−)-Cocaine PET Studies in Human Subjects , 1990, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[62] H. Braak,et al. The presubicular region in Alzheimer's disease: topography of amyloid deposits and neurofibrillary changes , 1989, Brain Research.
[63] Satoru Kawai,et al. An Algorithm for Drawing General Undirected Graphs , 1989, Inf. Process. Lett..
[64] K. Ogomori,et al. Beta-protein amyloid is widely distributed in the central nervous system of patients with Alzheimer's disease. , 1989, The American journal of pathology.
[65] T. Powell,et al. The Neuroanatomy of Alzheimer's Disease , 1989, Reviews in the neurosciences.
[66] G. V. Van Hoesen,et al. Alzheimer's disease: cell-specific pathology isolates the hippocampal formation. , 1984, Science.
[67] C. P. Hughes,et al. A New Clinical Scale for the Staging of Dementia , 1982, British Journal of Psychiatry.
[68] A. Nappi,et al. Alzheimer ' s Disease : Cell-Specific Pathology Isolates the Hippocampal Formation , 2022 .